US stocks benefit when rates rise with growth because earnings outpace the drag from higher discount rates. Such periods have historically been very bullish, unlike inflation-led rate rises amid slowing growth. Since fall 2025 the 10-year yield rose from 4.1% to 5.1% while nominal GDP growth accelerated to 6.6%, faster than rates. Being long offers better risk/reward; high oil prices due to the war are the remaining inflation pressure, and an end to the war would improve the setup further. x.com 

Biotech stocks can keep breaking out because AI is set to create a biotech boom and rate cuts look likely. Fears of higher rates came when oil was $112; with oil now under $70, rates should come down. x.com 

Rate-sensitive stocks look set to outperform as the market looks ahead to rates nearing a peak. After four years to price in inflation, these sectors have been severely punished, are excessively cheap and nobody owns them, and their divergence from bonds reflects that anticipation. Biotech showed a confluence of bullish factors earlier this year, airlines and real estate followed, and fintech now looks primed, despite lingering skepticism over rate and oil pressures. x.com  x.com 

Fintech is investing while biotech is gambling: roughly 90% of biotechs fail versus 10% of fintechs. Most fintechs are growing 25-30% or more yet trade at record-low valuations, while biotech is already up 90% and in a bubble driven by buyout mania. x.com 

Oil stabilizing or falling would ease inflation and open the door to lower interest rates, supporting a market rebound. At current oil levels, a few more painful months may give way to recovery; falling oil would accelerate it into an everything rally. If oil instead rises above $100 and stays there, the S&P 500 probably has a down year in 2027. x.com 

Biotech stocks are breaking out of a five-year range because the threat from oil and interest rates was priced in years ago. Many of the most undervalued growth stocks are now in biotech, and research discovery is getting a boost from AI, making it perhaps the sector with most to gain from AI productivity. Charts support it: daily volume spikes have tended to mark major bottoms, the weekly held its quarterly averages to form a base, and the monthly shows a healthy pullback to the one-year EMA. … Show more

Biotech looks weak as rates finally appear to be weighing on the sector. The biotech ETF closed red well below its 50-day moving average, its 100-day is below its 150-day, and the chart is messy. x.com 

Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com  x.com 

Biotech looks like a sector that wants to trend higher. Biotech M&A drove a heavy-volume weekly move to the top of a multi-month range; it just needs some help from the macro environment. x.com 

Property and casualty insurers such as W.R. Berkley should benefit as rates stay higher for longer, because their short-duration insurance float reprices higher, as in the 2022 hiking cycle. The Fed just hiked for the first time in over three years, while drone strikes shut Saudi Arabia's Petroline, which moved about 4 million barrels a day, sending Brent up 8.7% to $104.61 and the 10-year yield to 4.97%. That is a structural repricing of energy risk, and rate-cut bets will get run over. x.com